Palatin Technologies, Inc. (PTN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Palatin Technologies, Inc. (PTN) closed at USD 7.42 on 2026-10-14, a change of +24.7 % over the past year, with a market capitalization of USD 11.56M.

Palatin Technologies, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Palatin Technologies, Inc. key figures

Previous close

USD 7.42 (2026-10-14)

1-year change

+24.7 %

Market cap

USD 11.56M

Enterprise value

USD 4.29M

P/E ratio (trailing)

-2.77

P/E ratio (forward)

-3.50

EPS (trailing)

-2.34

EPS (forward)

-1.86

PEG ratio

1.62

Price to book

1.73

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.69

Employees

25

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Palatin Technologies, Inc.

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases. licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Princeton, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Palatin Technologies, Inc. and compare it with other stocks.